INBP (Integrated Biopharma) Cash And Cash Equivalents : $2.46 Mil (As of Dec. 2024)

View and export this data going back to 1996. Start your Free Trial

What is Integrated Biopharma Cash And Cash Equivalents?

Integrated Biopharma's quarterly cash and cash equivalents increased from Jun. 2024 ($1.68 Mil) to Sep. 2024 ($2.27 Mil) and increased from Sep. 2024 ($2.27 Mil) to Dec. 2024 ($2.46 Mil).

Integrated Biopharma's annual cash and cash equivalents increased from Jun. 2022 ($0.33 Mil) to Jun. 2023 ($1.32 Mil) and increased from Jun. 2023 ($1.32 Mil) to Jun. 2024 ($1.68 Mil).

Integrated Biopharma Cash And Cash Equivalents Historical Data

The historical data trend for Integrated Biopharma's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Integrated Biopharma Cash And Cash Equivalents Chart

Integrated Biopharma Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Cash And Cash Equivalents

Get a 7-Day Free Trial

0.40

0.21

0.33

1.32

1.68

Integrated Biopharma Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Cash And Cash Equivalents	Get a 7-Day Free Trial															0.73	2.02	1.68	2.27	2.46

Integrated Biopharma Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Integrated Biopharma (OTCPK:INBP) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Integrated Biopharma Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Integrated Biopharma's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Integrated Biopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Integrated Biopharma Inc (OTCPK:INBP) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

225 Long Avenue, Building 15, Hillside, NJ, USA, 07205

Website

https://ir.ibiopharma.com

Integrated Biopharma Inc is a pharmaceutical company engaged in manufacturing, distributing, marketing, and selling vitamins, nutritional supplements, and herbal products. It operates in two segments; Contract Manufacturing and Other Nutraceutical Businesses. Key revenue is generated from Contract Manufacturing segment which manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers and specialized health-care providers.

Executives

Damon Desantis	director	2424 N FEDERAL HIGHWAY, SUITE 208, BOCA RATON FL 33431
William H. Milmoe	director, 10 percent owner	3299 N.W. 2ND AVENUE, BOCA RATON FL 33431
Joseph Laplaca	director	72 EUGENE DRIVE, MONTVILLE NJ 07045
E Gerald Kay	director, 10 percent owner, officer: Chairman and CEO	C/O 225 LONG AVENUE, HILLSIDE NJ 07205
Bradley J Hoecker	director	STONINGTON PARTNERS, INC., 540 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10022
Jeffrey R Leach	director, officer: President and CEO
Glenn Chang	director	C/O IBIO, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
Vidadi Yusibov	director	C/O IBIOPHARMA, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
Cd Financial, Llc	10 percent owner	3299 N.W. 2ND AVENUE, BOCA RATON FL 33431
Kay Riva	director, officer: Vice President	C/O 225 LONG AVENUE, HILLSIDE NJ 07205
Christina Kay	director, officer: Vive President	C/O 225 LONG AVENUE, HILLSIDE NJ 07205
Robert Canarick	director	C/O INTEGRATED BIOPHARMA, INC., 201 ROUTE 22, HILLSIDE NJ 07205
Robert Kay	director	C/O IBIO, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
Dina Masi	officer: Chief Financial Officer	14 LEXINGTON WAY, LONG VALLEY NJ 07853
Carl Desantis	director, 10 percent owner	C/O CDS INTERNATIONAL HOLDINGS, 3299 NW SECOND AVE, BOCA RATON FL 33431